Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Evaluating the role of autoSCT in patients with DLBCL who relapse after first-line therapy

Daniel Landsburg • 14 Jun 2023
ICML 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Daniel Landsburg, MD, University of Pennsylvania, Philadelphia, PA, briefly discusses the important role of autologous stem cell transplantation (autoSCT) for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after first-line treatment, particularly comparing this treatment to CAR-T therapy. Dr Landsburg also comments on the value of using advanced molecular testing to determine the best therapy for a patient. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Landsburg

1:16
Predictors of long-term survival in patients with DLBCL/HGBCL following autoSCT
Daniel Landsburg • 14 Jun 2023
1:50
Outcomes of patients with DLBCL following ASCT and/or CAR-T
Daniel Landsburg • 14 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals